Report

Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease

See allHide authors and affiliations

Science  17 Oct 2014:
Vol. 346, Issue 6207, pp. 363-368
DOI: 10.1126/science.1259077

Abstract

T cells that mediate autoimmune diseases such as rheumatoid arthritis (RA) are difficult to characterize because they are likely to be deleted or inactivated in the thymus if the self antigens they recognize are ubiquitously expressed. One way to obtain and analyze these autoimmune T cells is to alter T cell receptor (TCR) signaling in developing T cells to change their sensitivity to thymic negative selection, thereby allowing their thymic production. From mice thus engineered to generate T cells mediating autoimmune arthritis, we isolated arthritogenic TCRs and characterized the self antigens they recognized. One of them was the ubiquitously expressed 60S ribosomal protein L23a (RPL23A), with which T cells and autoantibodies from RA patients reacted. This strategy may improve our understanding of the underlying drivers of autoimmunity.

Finding the targets of T cells gone bad

Autoimmune diseases such as rheumatoid arthritis can result when the immune system attacks its own body. If we could identify the specific proteins targeted by autoimmune T cells, we might then be able to block this interaction, which might be useful therapeutically. Ito et al. identified one such target in mice that develop a disease similar to rheumatoid arthritis. Disease-causing T cells recognized a protein that is part of the ribosome, a large protein complex that catalyzes protein synthesis. They also found T cells specific for this protein in people with rheumatoid arthritis.

Science, this issue p. 363

T cells mediate a variety of autoimmune diseases (1, 2), likely through the recognition of self antigens. However, identification of the self antigens targeted by T cells in systemic autoimmune diseases such as rheumatoid arthritis (RA) has been technically difficult (35). This is because pathogenic T cells expressing high-affinity T cell receptors (TCRs) for ubiquitous self antigens may be largely deleted (i.e., negatively selected) in the thymus and scarcely detectable in the periphery or, if detected, in an inactivated state (6). This can be circumvented by altering TCR signaling, which changes the sensitivity of developing T cells to thymic selection and results in new dominant self-reactive TCR specificities that are causative of systemic autoimmune diseases (711). For example, a hypomorphic point mutation of ζ-associated protein 70 (ZAP-70), a TCR-proximal signaling molecule, causes T cell–mediated spontaneous autoimmune arthritis in mice, which resembles RA (8).

To identify ubiquitously expressed self antigens commonly targeted in mouse and human systemic autoimmune disease, we first examined whether the arthritogenic CD4+ T helper (TH) cells in BALB/c SKG mice, which develop autoimmune arthritis due to the ZAP-70 mutation, made use of a specific dominant TCR. We compared the arthritogenic capacity of SKG CD4+ T cells expressing different TCR Vβ subfamilies (fig. S1). Transfer of SKG CD4+ T cells expressing Vβ6, Vβ8.1/8.2, or Vβ10 into BALB/c Rag2−/− mice induced arthritis with similar severities. In addition, CDR3 gene segments of Vβ6+ CD4+ T cells in arthritic joints were diverse, with few common sequences among individual arthritic SKG mice (fig. S2 and tables S1 and S2). Thus, under the assumption that arthritogenic SKG CD4+ T cells are highly polyclonal and make use of various Vα and Vβ TCR chains, we attempted to isolate a single arthritogenic CD4+ T cell from a particular CD4+ T cell subpopulation—for example, those expressing Vα2 and Vβ6, which constituted ~1% of joint-infiltrating CD4+ T cells. To differentiate arthritogenic CD4+ T cells from forkhead box P3 (Foxp3)–expressing CD4+ regulatory T (Treg) cells (1), we used SKG mice with knock-in of enhanced green fluorescent protein (EGFP)–Foxp3 fusion protein, designated eFOX SKG mice, which also spontaneously developed arthritis (fig. S3). We cloned a single TCR pair from individual GFP Vα2+ Vβ6+ CD4+ T cells present in arthritic joints of eFOX SKG mice, transfected Rag2−/− SKG bone marrow (BM) cells with the TCR gene, and transferred the BM cells into Rag2−/− mice to construct retrogenic mice expressing the TCR pair in developing T cells (1215). Among nine retrogenic strains each expressing a distinct TCR, those expressing 7-39 or 6-39 TCRs spontaneously developed arthritis at incidences of 80.0% and 27.3%, respectively (Fig. 1, A to C, and fig. S4, A to C). The two arthritogenic TCRs and a control nonarthritogenic 1-23 TCR used the same Vα and Vβ gene segments but different Jα and Jβ genes and CDR3 sequences (Fig. 1A). Arthritic joints in retrogenic 7-39 (R7-39) mice showed mononuclear cell infiltration, pannus formation, and cartilage destruction (Fig. 1D). Some (66.7%) of the R7-39, but not the R6-39, mice also developed chronic dermatitis, which exhibited hyperkeratosis and parakeratosis, histopathological features of human psoriasis (16) (Fig. 1, E and F, and fig. S5). Other organs were histologically intact (fig. S6).

Fig. 1 Arthritis-inducing activity of two TCRs individually expressed in retrogenic mice.

(A) Amino acid sequences and frequencies of two arthritogenic TCRs (7-39 and 6-39) and the nonarthritogenic 1-23 TCR. These three TCRs were obtained from three different mice. CDR, complementarity-determining region. Amino acid abbreviations: A, Ala; C, Cys; E, Glu; F, Phe; G, Gly; I, Ile; K, Lys; L, Leu; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; Y, Tyr. (B) Joint swelling in R7-39 retrogenic mice. (C) Incidence and scores of spontaneous arthritis in R7-39 (n = 11), R1-23 (n = 14), and W7-39 mice (n = 8). Error bars indicate means ± SD. (D) Hematoxylin and eosin (HE) staining of arthritic joints; scale bar, 1 mm. (E) Ears and hind paws of R7-39 and R1-23 mice. (F) HE staining of ears from R7-39 and R1-23 mice; scale bar, 500 μm. Results in (B) and in (D) to (F) represent three independent experiments.

In R7-39 mice, 7-39 TCR–transduced cells preferentially differentiated into monoclonal CD4+ T cells with an activated and memory phenotype (fig. S7), and were able to transfer both arthritis and dermatitis into other Rag2−/− mice. Both arthritic R7-39 and nonarthritic R1-23 mice failed to develop Foxp3+ Treg cells (fig. S8). In contrast to 7-39 TCR gene–transfected Rag2−/− BM cells with the SKG ZAP-70 mutation, 7-39 TCR gene–transfected ZAP-70–intact Rag2−/− BALB/c BM cells did not cause arthritis in retrogenic mice (designated W7-39 mice). In W7-39 mice, the majority of 7-39 TCR–expressing CD4+ T cells were negatively selected in the thymus, and those that had escaped thymic negative selection exhibited a naïve nonactivated phenotype, indicating their dormant or anergic state (Fig. 1C and fig. S9).

Taken together, these results demonstrate that CD4+ T cells with a specific TCR mediate autoimmune arthritis and also dermatitis, and that more than one TCR specificity is individually able to confer T cell arthritogenicity.

We next constructed T cell hybridomas expressing 7-39 or 6-39 TCRs and attempted to determine the self antigens recognized by these TCRs. The 7-39 hybridoma cells produced interleukin-2 (IL-2) when stimulated by cell extracts not only from SKG fibroblast-like synoviocytes (FLSs) but also from P3U1 cells, a BALB/c plasma cell–derived cell line (fig. S10). In contrast, syngeneic antigen-presenting cells (APCs) were sufficient to induce IL-2 production by 6-39 hybridoma cells, indicating that the 6-39 TCRs recognized a self antigen constitutively displayed by APCs (fig. S4D). To further characterize the self antigen recognized by 7-39 TCRs, we reconstituted Rag2−/− mice with a mixture of 7-39 TCR–transfected Rag2−/− SKG BM cells and TCRβ−/− BALB/c BM cells on the assumption that the autoantibodies produced by B cells might specifically react with the self antigen recognized by 7-39 TCRs because T cell help came solely from 7-39 TH cells. The sera from these “B cell–reconstituted” mice specifically reacted with an 18-kD protein from the cell extract of P3U1 cells (Fig. 2A). Mass spectrometric analysis identified this protein as RPL23A, a component of the 60S subunit of ribosomes (17, 18) (fig. S11). Various organs were found to express RPL23A mRNA at high levels (Fig. 2B). The amino acid sequence of RPL23A is 100% conserved between mice and humans (18). The sera from the B cell–reconstituted R7-39 mice indeed recognized recombinant RPL23A, but not histone H1.2 protein, another candidate protein indicated by the mass spectrometric analysis (Fig. 2C). In addition, recombinant RPL23A protein specifically stimulated the 7-39 hybridoma cells in a dose-dependent, class II major histocompatibility complex (MHC) I-Ad–dependent manner (Fig. 2D and fig. S12). Among 20–amino acid RPL23A peptides with consecutive overlapping of 5 amino acid residues, RPL23A71-90 peptide stimulated 7-39 TCRs most potently (table S3 and fig. S13A).

Fig. 2 Identification of the self antigen recognized by arthritogenic 7-39 TCRs.

(A) Immunoblot analysis by sera from B cell–reconstituted R7-39 mice (n = 7) and B cell–reconstituted R1-23 mice (n = 3). Arrow indicates the commonly recognized protein. (B) Quantitative real-time polymerase chain reaction (qPCR) analysis for RPL23A gene expression in various tissues from SKG mice (n = 3). Error bars indicate means ± SD. (C) Recombinant RPL23A protein revealed by immunoblotting with sera from the indicated mice. (D) IL-2 production by 7-39 or 1-23 T cell hybridomas stimulated with the indicated recombinant proteins (n = 6). Horizontal bars indicate the means. *P < 0.05 (Kruskal-Wallis test followed by Steel-Dwass test). Results represent two [(A) to (C)] or three (D) independent experiments.

B cell–reconstituted R7-39 mice and arthritic SKG mice developed antibodies reacting with cyclic citrullinated peptides (CCP), as also observed in RA patients (19) (fig. S14A), yet there was no significant difference in titer of antibodies to RPL23A whether this was assessed with citrullinated or noncitrullinated RPL23A protein (fig. S14, B and C). In addition, the RPL23A71-90 peptide recognized by 7-39 TCRs contained no arginine residue to be converted to citrulline (table S3).

Taken together, these results indicate that the ubiquitously expressed protein RPL23A can be a target antigen of both arthritis and dermatitis. Furthermore, more than one systemic antigen can be targeted for arthritis induction, because the 6-39 TCRs did not react to peptides derived from RPL23A (fig. S13B).

Upon transfer, CD4+ T cells, but not sera, from B cell–reconstituted R7-39 mice induced arthritis in Rag2−/− mice (fig. S15). Indeed, CD4+ T cells from arthritic joints or the regional lymph nodes of R7-39 mice produced inflammatory cytokines [including IL-17A, interferon-γ (IFN-γ), and granulocyte macrophage-colony stimulating factor (GM-CSF)] upon activation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, RPL23A protein, or RPL23A71-90 peptide (Fig. 3, A to D, fig. S16, A to D, and fig. S17). In addition, RPL23A stimulated nonarthritic SKG, but not BALB/c, CD4+ T cells to produce IL-17A in vitro (Fig. 3E). It also augmented the production of IL-17A by CD4+ T cells from SKG mice treated with mannan, which can trigger autoimmune arthritis in SKG mice by promoting TH17 differentiation of arthritogenic CD4+ T cells (20, 21). An arthritic joint of SKG mice indeed harbored CD4+ T cells possessing the Vβ CDR3 of 7-39 TCRs (table S2).

Fig. 3 RPL23A-reactive TH cells in R7-39 mice.

(A) Cytokine production by CD4+ T cells from regional lymph nodes of R7-39 or R1-23 mice after in vitro stimulation with recombinant RPL23A or control glutathione S-transferase (GST) protein. Stim, stimulation. Data are representative of three independent experiments. (B) Percentages of cytokine-producing CD4+ T cells in (A) (n = 3). (C) Cytokine amounts in culture supernatants in (A) (n = 6). (D) IL-17A production by RPL23A-stimulated lymphocytes from R7-39 mice in the presence or absence of blocking antibodies to MHC class I or class II (n = 6). (E) IL-17A production by lymphocytes stimulated with recombinant RPL23A or control GST proteins (n = 8). Lymphocytes were taken from SKG or BALB/c mice with or without mannan treatment. In (B), results are shown as means ± SD. In (C) to (E), horizontal bars indicate the means; *P < 0.05 (Kruskal-Wallis test followed by Steel-Dwass test); NS, not significant. Results represent two independent experiments in (B) and (C).

We next evaluated the contribution of Treg cells to controlling arthritogenic CD4+ T cells. Treg cells from either ZAP-70–intact BALB/c or ZAP-70–mutant SKG mice failed to suppress arthritis development in Rag2−/− mice when cotransferred with phenotypically activated or memory 7-39 TCR+ CD4+ T cells (figs. S7 and S18), although Treg cells were capable of suppressing naïve arthritogenic T cells effectively (9).

These results collectively indicate that RPL23A is able to stimulate CD4+ T cells in R7-39 mice via RPL23A-derived peptide–MHC class II complexes, driving them to differentiate into arthritogenic effector TH cells (20), which are capable of mediating arthritis even in the presence of Treg cells.

Lastly, we examined possible immune responses to RPL23A in RA patients. RPL23A mRNA was found to be ubiquitously expressed in healthy human tissues (Fig. 4A). In synovial tissues of RA patients and also in the apparently normal synovial tissues of osteoarthritis (OA) patients, RPL23A was detected in the cytoplasm of synovial cells, including CD55+ FLSs (Fig. 4B). Relative to healthy controls (1.3%, n = 74), a significantly higher proportion of RA patients (16.8%, n = 374) were positive for serum immunoglobulin G–type autoantibodies to RPL23A (Fig. 4C). Two out of 23 psoriatic arthritis (PsA) patients (8.7%) were positive for the autoantibody, whereas all of the OA patients (n = 11), systemic lupus erythematosus (SLE) patients (n = 30), or polymyositis/dermatomyositis (PM/DM) patients (n = 10) were negative. In addition, in the synovial fluid of a subset of RA patients, we detected CD4+ T cells producing IFN-γ upon stimulation with RPL23A (Fig. 4, D and E). These findings in humans, together with the key role of anti-RPL23A T cell responses for autoimmune arthritis and psoriasis-like dermatitis in mice, suggest that the responses may play a pathogenic role at least in a subset of patients with RA or PsA.

Fig. 4 Anti-RPL23A humoral and cellular immune responses in RA patients.

(A) qPCR analysis of RPL23A gene expression in various tissues from healthy human subjects (n = 3). Results are shown as means ± SD and represent two independent experiments. (B) Immunohistochemical staining of synovial tissues from RA or OA patients for RPL23A or CD55 expression (scale bars, four images at left, 200 μm; two images at right, 50 μm). Serial sections were stained by anti-RPL23A, anti-CD55, or control antibody. Arrows indicate cells that are both RPL23A- and CD55-positive. Representative results from three patients are shown. (C) Serum levels of autoantibodies to RPL23A assessed by enzyme-linked immunosorbent assay (ELISA) in RA, PsA, OA, SLE, and PM/DM patients or healthy individuals. Horizontal bars indicate the medians. ***P < 0.001 (Kruskal-Wallis test followed by Dunn’s multiple comparison test). (D) Cytokine production from CD4+ T cells stimulated with recombinant RPL23A or GST protein. (E) Percentages of IFN-γ+ cells in RPL23A- or GST-stimulated CD4+ T cells in RA patients (n = 24) or healthy individuals (n = 9). *P < 0.05 (χ2 test). Dashed lines indicate the threshold in (C) and (E).

Our results show that by attenuating TCR signal intensity in developing T cells (hence reducing their sensitivity to thymic negative selection by natural self ligands), T cells reactive with ubiquitously expressed self antigens can be generated as dominant pathogenic clones causing systemic autoimmune disease. Because similar attenuation of TCR signaling at various degrees in conjunction with Treg cell depletion is able to produce a variety of other autoimmune diseases in mice (9, 22), this strategy of generating pathogenic T cells and characterizing the self antigens they recognize would facilitate our understanding of the mechanisms of other autoimmune diseases of currently unknown etiology. In addition, given that genetic polymorphism in a signaling molecule in T cells is a major determinant of genetic susceptibility to various human autoimmune diseases including RA (23), such a genetic variation might, at least in part, alter thymic selection, hence forming a TCR repertoire for causing autoimmune disease. Our approach may also be useful in deciphering how T cell autoimmunity to a ubiquitous self antigen triggers localized tissue damage in RA and other human autoimmune diseases, and in devising effective means of systemic or local intervention in the disease process.

Supplementary Materials

www.sciencemag.org/content/346/6207/363/suppl/DC1

Materials and Methods

Supplementary Text

Figs. S1 to S18

Tables S1 to S3

References (2436)

References and Notes

  1. See supplementary materials on Science Online.
  2. Acknowledgments: We thank D. O. Adeegbe, Y. Kitagawa, and K. Chen for critical reading of the manuscript; E. Yamamoto, M. Matsuura, R. Ishii, Y. Tada, Y. Funabiki, the technical support team (Graduate School of Medicine, Kyoto University), and K. Saito of DNA-chip Development Center for Infectious Diseases (RIMD, Osaka University) for technical assistance; T. Matsushita for histology; T. Kitamura for gifts of the packaging cell line Plat-E; the members of the Department of Rheumatology and Clinical Immunology, Kyoto University, for providing us with patients’ sera; and the members of our laboratories for comments. The data presented in this paper are tabulated in the main paper and in the supplementary materials. eFOX mice and plasmids for making retrogenic mice are subject to a material transfer agreement. A patent application related to the work in this paper has been filed (PCT/JP2014/069306: A way to diagnose autoimmune arthritis; Y.I. and S.S. as inventors). Supported by Grants-in-Aid for Specially Promoted Research 20002007 (S.S. and Y.I.),;for Young Scientists (B) 24790996 (Y.I.) from the Japan Society for the Promotion of Science; Core Research for Evolutional Science and Technology from the Japan Science and Technology Agency (S.S.); NIH grant R01 DK089125 (D.A.A.V.); and American Lebanese Syrian Associated Charities (D.A.A.V.). M.H., T.F., M.F., H.I., and T.M. are affiliated with a department that is supported financially by five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Bristol-Myers K.K., Chugai Pharmaceutical Co. Ltd., AbbVie GK., and Eisai Co. Ltd.). The sponsors were not involved in the study design; in the collection, analysis, or interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication.
View Abstract

Stay Connected to Science

Navigate This Article